Miyagawa, Shigeru http://orcid.org/0000-0003-0015-6569
Kawamura, Takuji
Ito, Emiko
Takeda, Maki
Iseoka, Hiroko
Yokoyama, Junya
Harada, Akima
Mochizuki-Oda, Noriko
Imanishi-Ochi, Yukiko
Li, Junjun
Sasai, Masao
Kitaoka, Fumiyo
Nomura, Masaki
Amano, Naoki
Takahashi, Tomoko
Dohi, Hiromi
Morii, Eiichi
Sawa, Yoshiki
Funding for this research was provided by:
Japan Agency of Medical Research and Development (JP20bm0204003)
Japan Agency for Medical Research and Development (JP17bk0104044)
Article History
Received: 22 September 2022
Accepted: 28 February 2024
First Online: 13 March 2024
Declarations
:
: This study complied with the Declaration of Helsinki, the ethics committees approved all research protocols (Studies on cardiac differentiation using clinical grade iPS cell stocks derived from HLA homozygous donors; Ethical Review Board of Osaka University Hospital; 14306–7; November 4, 2014), and informed consent was obtained from the study participant. All experimental procedures and protocols involving animals were performed in accordance with the national regulations and guidelines, reviewed by the Committee for Animal Experiments, approved by the president of Osaka University (Examination of optimal cell number and purity in myocardial regeneration treatment using hiPSC-CM sheet transplantation in a pig ischemic heart disease model; The Institute of Experimental Animal Sciences Faculty of Medicine, Osaka University; Approval number 25-110-012; February 12, 2014. Study on heart failure treatment, safety, and immune response using iPSC-CMs; The Institute of Experimental Animal Sciences Faculty of Medicine, Osaka University; Approval number 30-019-010; March 26, 2018.) and conducted in compliance with the ARRIVE guidelines.
: Not applicable.
: The authors declare that they have no competing interests.